Sugi Predict

Sugi Predict / Compounds / SCHEMBL3225152

SCHEMBL3225152

SCHEMBL3225152

O/N=C/c1ccc(Cl)c(Cl)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.58
▸ NPFFR2 Q9Y5X5 2/20 0.58
▸ NPSR1 Q6W5P4 1/20 0.58
▸ ALDH1A1 P00352 3/20 0.52
▸ LMNA P02545 1/20 0.51
▸ NPC1 O15118 4/20 0.50
▸ RAB9A P51151 4/20 0.50
▸ SMN1; SMN2 Q16637 4/20 0.50
▸ NFKB1 P19838 2/20 0.50
▸ NFKB2 Q00653 2/20 0.50
▸ RELA Q04206 2/20 0.50
▸ L3MBTL1 Q9Y468 2/20 0.50
▸ KDM4E B2RXH2 1/20 0.50
▸ THRB P10828 1/20 0.47
▸ G6PC1 P35575 1/20 0.46
▸ MAPT P10636 2/20 0.45
▸ MEN1 O00255 1/20 0.41
▸ HSP90AA1 P07900 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2164853 1.00 KMT2A (0.58) KMT2ANPFFR2NPSR1ALDH1A1LMNA
SCHEMBL2164856 1.00 KMT2A (0.58) KMT2ANPFFR2NPSR1ALDH1A1LMNA
SCHEMBL17548936 0.83 LMNA (0.49) KMT2ANPFFR2NPSR1ALDH1A1LMNA
SCHEMBL20745432 0.81 SMN1; SMN2 (0.46) KMT2ANPFFR2NPSR1ALDH1A1LMNA
SCHEMBL2164811 0.81 ALDH1A1 (0.46) KMT2ANPFFR2NPSR1ALDH1A1LMNA
SCHEMBL978767 0.81 LMNA (0.47) KMT2ANPFFR2NPSR1ALDH1A1LMNA
SCHEMBL112321 0.81 LMNA (0.47) KMT2ANPFFR2NPSR1ALDH1A1LMNA
SCHEMBL22613823 0.81 SMN1; SMN2 (0.49) KMT2ANPFFR2NPSR1ALDH1A1LMNA
SCHEMBL22613822 0.81 SMN1; SMN2 (0.49) KMT2ANPFFR2NPSR1ALDH1A1LMNA
SCHEMBL2164812 0.81 ALDH1A1 (0.46) KMT2ANPFFR2NPSR1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116236478-A Application of aromatic heterocyclic formamide compound 浙江大学 2023-06-09 — — CN disclosed
US-9326930-B2 Calcium sequestration compositions and methods of treating skin pigmentation disorders and conditions NEOCUTIS S.A. (CH) 2016-05-03 — — US disclosed
US-9326930-B2 Calcium sequestration compositions and methods of treating skin pigmentation disorders and conditions NEOCUTIS S.A. (CH) 2016-05-03 — — US disclosed
US-20160030321-A1 CALCIUM SEQUESTRATION COMPOSITIONS AND METHODS OF TREATING SKIN PIGMENTATION DISORDERS AND CONDITIONS NEOCUITIS S A (CH) 2016-02-04 — — US disclosed
US-20160030321-A1 CALCIUM SEQUESTRATION COMPOSITIONS AND METHODS OF TREATING SKIN PIGMENTATION DISORDERS AND CONDITIONS NEOCUITIS S A (CH) 2016-02-04 — — US disclosed
US-20160030321-A1 CALCIUM SEQUESTRATION COMPOSITIONS AND METHODS OF TREATING SKIN PIGMENTATION DISORDERS AND CONDITIONS NEOCUITIS S A (CH) 2016-02-04 — — US disclosed
WO-2015066371-A1 SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS FORUM PHARMACEUTICALS, INC. (US) 2015-05-07 — — WO disclosed
WO-2015066371-A1 SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS FORUM PHARMACEUTICALS, INC. (US) 2015-05-07 — — WO disclosed
US-8815935-B2 Inhibitors of protein prenyltransferases THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-08-26 — — US disclosed
US-20130102639-A1 INHIBITORS OF PROTEIN PRENYLTRANSFERASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-04-25 — — US disclosed
US-20040110804-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-06-10 — — US disclosed
WO-2004004657-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-01-15 — — WO disclosed
US-20030176495-A1 HIV Integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2003-09-18 — — US disclosed
EP-1328534-A2 6-O-SUBSTITUTED ERYTHROMYCIN DERIVATIVES HAVING IMPROVED GASTROINTESTINAL TOLERANCE Abbott Laboratories (US) 2003-07-23 — — EP disclosed
WO-2003049690-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-06-19 — — WO disclosed
WO-2002032919-A2 6-O-SUBSTITUTED ERYTHROMYCIN DERIVATIVES HAVING IMPROVED GASTROINTESTINAL TOLERANCE ABBOTT LABORATORIES (US) 2002-04-25 — — WO disclosed
US-6057352-A CONTROLLING PLANT DISEASES CAUSED BY FUNGAL PLANT PATHOGENS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2000-05-02 — — US disclosed
EP-0825988-A1 FUNGICIDAL CYCLIC AMIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1998-03-04 — — EP disclosed
WO-1996036616-A1 FUNGICIDAL CYCLIC AMIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1996-11-21 — — WO disclosed
US-4581365-A Trichloroacryloyl oxime fungicides NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) 1986-04-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110804-A1 HIV integrase inhibitors CDKN1A, SAMHD1, CTCF KMT2A 736/4885NPFFR2 4665/4885NPSR1 4603/4885
US-20030176495-A1 HIV Integrase inhibitors MAPT, RIF1, HPRT1 KMT2A 646/4885NPFFR2 4653/4885NPSR1 4477/4885
US-20160030321-A1 CALCIUM SEQUESTRATION COMPOSITIONS AND METHODS OF TREATING SKIN PIGMENTATION DISORDERS AND CONDITIONS S100A4, TYR, CACYBP KMT2A 3288/4885NPFFR2 3366/4885NPSR1 3343/4885
US-20130102639-A1 INHIBITORS OF PROTEIN PRENYLTRANSFERASES RABGGTA, FNTA, RABGGTB KMT2A 2553/4885NPFFR2 4814/4885NPSR1 4798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.